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Abstract 
In recent years different sub-phenotypes of obesity have been described including metabolically 
healthy obesity (MHO), whereby a proportion of obese individuals despite excess body fat remain 
free of metabolic abnormalities and increased cardiometabolic risk. In the absence of a universally 
accepted set of criteria to classify MHO the reported prevalence estimates vary widely. Our 
understanding of the determinants and stability of MHO over time and associated cardiometabolic and 
mortality risk is improving, but many questions remain. For example, whether MHO is truly benign is 
debatable and whether risk stratification of obese individuals based on their metabolic health status 
may offer new opportunities for more personalised approaches in diagnosis, intervention and 
treatment of diabetes remains speculative. Furthermore, as most research to date has focussed on 
MHO in adults little is known about childhood MHO. In this review we focus on the epidemiology, 
determinants, stability and health implications of MHO across the life course.  
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Introduction 
Obesity has become a worldwide epidemic and represents a major public health challenge. Over the 
last four decades, there has been a global shift from a time when underweight was twice as prevalent 
as obesity to one in which the numbers of obese individuals now surpass those who are underweight, 
both globally and in all regions, with the exceptions of areas of Asia and sub-Saharan Africa 
1
. 
Examination of body mass index (BMI) trends from 1698 population-based data sources involving 
more than 19.2 million adults (9.9 million men and 9.3 million women) revealed that in 2014 the 
prevalence of obesity exceeded underweight in both men and women  in 68% and 83% of the 
countries for whom estimates were available 
1
. Recent estimates indicate that about 266 million men 
and 375 million women are obese in the world 
1
. Future projections predict that over one billion 
people, or approximately 20% of the world’s entire adult population, will be obese by 2030 2. Not 
only is the prevalence of adult obesity increasing so too is childhood obesity. Approximately one 
quarter of children worldwide are overweight or obese 
3, 4
. Although there are indications that the 
prevalence of overweight and obesity in children is plateauing in some populations 
4
, current levels 
remain high. This is particularly concerning as it has been shown that childhood obesity tracks to 
adulthood and is associated with increased risk of cardiometabolic disease and premature mortality 
5
.  
The current obesity epidemic is paralleled by escalating prevalence of type 2 diabetes mellitus 
(T2DM) and metabolic syndrome (MetS), a constellation of metabolic perturbations including 
obesity, insulin resistance, hypertension and dyslipidaemia. However over recent years it has become 
increasingly recognised that obesity is not a homogeneous condition and that a subset of obese 
individuals do not display disturbed metabolic profiles or increased risk of cardiometabolic disease. 
As such these individuals, who are characterised by preserved insulin sensitivity, normal blood 
pressure and lipid profiles despite their adiposity, may be described as being metabolically healthy 
obese (MHO). Similarly there exist normal weight individuals who display abnormal metabolic 
profiles and carry increased cardiometabolic risk. Thus a spectrum of metabolic health phenotypes 
according to BMI or body composition exist, ranging from metabolically healthy normal weight to 
metabolically unhealthy obese (MUO), along which MHO represents an intermediate stage. Research 
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on obesity phenotypes has mainly focussed on MHO among adults to date with a paucity of 
information available on childhood MHO. Therefore, in this review we focus on the epidemiology, 
determinants, stability and health implications of MHO over the life course from childhood into 
adulthood.  
 
Metabolically healthy obesity in childhood and adolescence 
The currently increasing prevalence of a range of adult chronic non-communicable diseases, including 
obesity, cannot be explained solely by genetic or adult lifestyle factors. Evidence from 
epidemiological studies suggest that the origins of many chronic diseases, including obesity, MetS, 
cardiovascular disease (CVD) and T2DM, actually begin in early life and that childhood insulin 
resistance and adiposity predispose to diabetes, MetS and CVD in adulthood  
6-10
.  Increasing evidence 
also suggests that early life exposure to a range of environmental factors, including nutrition for 
example, plays a critical role in defining offspring health, both in childhood and in later life. 
According to the Developmental Origins of Health and Disease hypothesis, transient environmental 
exposures during critical periods of development (such as the pre-conceptional, fetal and early infant 
phases of life) can alter normal physiology and have a persistent impact on metabolism and gene 
expression thereby influencing offspring phenotype and disease risk in later life 
11, 12
. For example, 
growth velocity in utero and in early life, which are a read-out of early nutritional status, may affect 
cardiovascular and cancer risk. Stefan et al., recently reviewed the literature on height (a genetically 
determined phenotype which is influenced by maternal and early life exposures) and cardiometabolic 
disease and cancer risk later in life 
13
. Accumulating data suggest divergent associations, such that 
height is associated with lower cardiometabolic risk and higher cancer risk.  The authors speculate 
that overnutrition, particularly of milk and dairy products, during child development may play a role. 
Thus avoiding such overnutrition during critical developmental periods may attenuate accelerated 
growth and development of obesity in children leading to lower cancer risk in later life. Therefore, 
investigating metabolic health and adiposity in childhood may have implications in terms of 
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preventative strategies for adverse metabolic health phenotypes in early life which may have long 
term impacts.  
As is the case for adults no standard metabolic health definition exists for use in children. Table 1 
details some currently used criteria to define MHO among children and adolescents 
14-20
. While 
metabolic health may be simply defined as the absence of insulin resistance 17, in the majority of 
studies MHO characterisation centres on the absence of MetS (or some of its cardiometabolic risk 
factors) 
14-20
 among those with excess body weight. It is important to note that how obesity is 
classified is also an issue, with different anthropometric measures and cut-offs being used. The 
Bogalusa Heart Study defined overweight/obesity as a BMI in the top quartile 
16
, the cross-sectional 
study by Prince et al.,  defined obesity as a BMI ≥85th percentile 17, the studies by Vukovic et al., 18, 19 
and Camhi et al., 
14, 21
 defined obesity as a BMI ≥95th percentile, whereas Zamrazilova et al., 20 used a 
BMI ≥97th percentile to classify obesity. The Korean Children-Adolescent Study was based on 
abdominal obesity assessed by waist circumference 
15
.  Such variation in classification of both obesity 
and metabolic health undoubtedly hinders comparisons between studies and contributes to the 
observed disparity in MHO prevalence in these studies (ranging from 4.2% 
16
, 21.5% 
17
, 21.7% 
18
, 
25% 
19
, 53% 
15
 to 68% 
14
). 
The determinants of and molecular mechanisms underlying MHO among children are under examined 
and as a result, poorly understood.  Collectively the data indicate that MHO children are more likely 
to be younger (and in earlier stages of puberty) and female, of high birth weight with less visceral fat, 
preserved insulin sensitivity, high adiponectin concentrations, altered ghrelin levels, more favourable 
lipid profiles, reduced concentrations of transaminases and uric acid, and without hepatic steatosis 
17-
19, 22-28
. Although early weight gain was originally identified as a determinant of childhood MHO 
23
 a 
larger study of Danish men for whom childhood BMI was available failed to find robust evidence to 
support a role for either rapid BMI growth or early-onset obesity in the development of MHO 
29
. 
Aside from laboratory and clinical based predictors limited data regards the role of environmental, 
lifestyle, behavioural or genetic factors in determining MHO status among children exist. Prince et 
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al., examined lifestyle predictors of MHO among 8-17 year olds attending a weight management 
clinic 
17
. They identified dietary fat intake and moderate-to-physical activity as independent 
predictors. In contrast Camhi et al., reported that physical activity, but not sitting or screen time 
differs between MHO and MUO in adults, but not in adolescents 
14
. In further work these authors also 
demonstrated that MHO adolescents have better compliance with dietary guidelines compared to their 
MUO counterparts 
21
. A study of 1213 Chinese children aged 6-18 years reported that walking to 
school and frequency of soft drink consumption, together with other demographic factors, contribute 
to the prediction of MHO status 
30
. Interestingly this study also examined 22 genetic variants 
previously identified from genome wide association studies of obesity and diabetes. They found that 
both genetic predisposition and lifestyle factors and their interaction are independent predictors of 
MHO. More recently a study of teenage boys (13-17.9 years) investigated a range of potential 
determinants of MHO including duration of exposure to obesity, dietary intake and lifestyle factors.  
With the exception of carbohydrate intake, no other associations with MHO were identified with 
dietary or lifestyle factors. However a clear relationship between early onset of obesity and longer 
duration of its exposure with MUO was demonstrated 
20
. Collectively these data suggest potential 
intervention windows and targets to improve cardiometabolic profiles in paediatric obesity with a 
view to achieving and maintaining better long term cardiometabolic health.  
 
Metabolically healthy obesity in adulthood  
The prevalence of MHO among adults varies greatly between studies. Although study specific 
differences such as age, ethnicity, sample size or environmental factors and genetics may be 
contributing factors, the lack of a universal definition of metabolic health and differences in obesity 
classification (BMI versus body fat percentage) account for a large proportion of the reported 
disparity 
31
. Table 2 details some currently used criteria to define MHO among adults 
32-38
. At the 
very least metabolic health may be defined as the absence of insulin resistance 
35
, but as is the case in 
children for the most part current characterisation of MHO in adults is based on the absence of MetS 
7 
 
(or some of its components) among those with excess body weight, generally defined by BMI 
34-38
. 
Some definitions additionally include favourable inflammatory status determined by C reactive 
protein levels 
32, 33
.  
Although limited, comparative studies examining MHO prevalence across a range of currently used 
criteria have reported considerable variation in MHO prevalence and poor agreement between MHO 
definitions 
39, 40
.  In an Irish cross-sectional population representative sample of adults aged 50-69 
years, among the obese (by BMI) participants MHO prevalence ranged from 6.8%-36.6% 
39
. MHO 
prevalence was generally higher among females and conflicting associations were noted with age, 
depending on which definitions were used.  In a Korean study of 186 obese (by BMI) male subjects 
Yoo et al., 
41
 reported MHO prevalence ranging from 24.2% to 70.4%. This study did not observe any 
age related differences, which may be accounted for by the narrow and younger age range of the male 
only study participants (mean age 37 years). In a Swiss population-based sample of adults aged 35-75 
years MHO prevalence ranged from 3.3-32.1% in men and 11.4-43.3% in women, with higher 
estimates reported when obesity was defined by body fat percentage (BF%) 
40
. The latter finding 
highlights the importance of how obesity is classified. Direct measurement of body fat using dual-
energy X-ray absorptiometry (DEXA) is the gold standard, however DEXA is generally not available 
or practical for most researchers. BMI is the most widely used method to classify excess adiposity, 
with values ≥ 30 kg/m2 indicating obesity. However BMI does not discriminate between fat and lean 
body mass, thus individuals of short stature or muscular build may be misclassified. Indeed, 
accumulating evidence indicates that BMI may actually under estimate obesity prevalence 
42
. 
Similarly, obesity classification influences MHO prevalence, with estimates ranging from a third to 
half of obese individuals by BMI and DEXA respectively 
43
. Furthermore, recent data suggest that 
combined assessment of BMI and body fat percentage or other anthropometric measures to classify 
obesity may help identify individuals at greater cardiometabolic risk than BMI alone 
44, 45
. 
Collectively these data underscore the importance of accurate obesity diagnosis in the context of more 
precise classification and risk stratification. 
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MHO prevalence has been recently examined in a number of large scale studies. Analysis of 10 cohort 
studies involving 163,517 individuals from 7 European countries revealed significant diversity in 
MHO prevalence across Europe (7-28% in women and 2-19% in men) 
38
. Generally, MHO, which 
was defined as obesity (by BMI) without any MetS component and no previous CVD diagnosis, was 
more prevalent among women and decreased with age in both genders 
38
. A worldwide meta-analysis 
of 31 studies reported overall prevalence of MHO of 7.27%, with highest prevalence among 
American populations, although wide ranges were reported between individual studies (MHO 
prevalence of 1.3-22.9% in Americans, 2.1-23.9% in Europeans and 2.8-25.8% in Asians) 
46
. Despite 
study design and population differences, the observed variation in MHO prevalence reported both in 
the comparative studies and meta-analyses highlight the need for larger scale population 
representative studies, improved obesity classification and a global consensus on a standard MHO 
definition.   
 
Characterisation and determinants of metabolically healthy obesity 
Although the determinants of MHO and the molecular mechanisms underlying the MHO phenotype 
are not fully elucidated, accumulating evidence is improving our understanding of the biological 
factors which distinguish MHO on the one hand from obesity per say, and on the other hand, from 
metabolically unhealthy obesity 
47, 48
. Here we summarise the recent literature regards determinants of 
metabolic health status, with a focus on potential biological, environmental and genetic factors 
involved in the pathogenesis of MHO.  
Adiposity and body composition  
It has been recognised that different body fat distribution patterns, most notably increased visceral 
adipose tissue (VAT) and ectopic fat deposition (intramuscular, hepatic and epicardial) are related to 
different metabolic phenotypes and obesity-related cardiometabolic risk 
49-51
. Greater VAT is 
associated with impaired glucose tolerance, insulin resistance, increased secretion of very low density 
lipoprotein (VLDL) and increased intra-hepatic triglyceride content (IHTG) 
52-56
. Hepatic fat has been 
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identified as a potential predictor of the MUO phenotype, type 2 diabetes and subclinical 
atherosclerosis 
57-61
. It has been hypothesised that how the body channels surplus energy, arising from 
a combination of excessive caloric intake, reduced physical activity and increased time spent in 
sedentary behaviour, may determine an individual’s predisposition to MHO or MUO. The pathway to 
MUO may be characterised by dysfunctional adipose tissue (larger fat cells), increased immune cell 
infiltration, raised pro-inflammatory status and reduced capacity of subcutaneous adipose tissue to 
expand leading to increased ectopic fat deposition resulting in lipotoxicity, insulin resistance in 
peripheral tissues and a range of metabolic derangements (Figure 1) 
62
. Whereas in MHO individuals 
the excess calories are channelled into insulin-sensitive subcutaneous adipose tissue which is capable 
of expansion, thus visceral and ectopic adiposity are reduced, macrophage infiltration and raised pro-
inflammatory state are attenuated, insulin sensitivity is preserved and the individual is protected from 
development of the MetS 
47, 63-66
. 
It has been questioned whether increased VAT is just an innocent bystander acting as a marker of 
ectopic fat deposition or is indeed the culprit 
67
. In a small study of 39 obesity-matched adolescents 
and adults Linder at al., compared the impact of body fat distribution and ectopic fat, in particular 
liver fat, on insulin resistance with a view to establishing whether previously identified relationships 
in adults between liver fat and insulin resistance hold true among adolescents. Despite having lower 
VAT the overweight and obese adolescents were more insulin resistant than the gender and BMI-
matched adults. Of note hepatic fat content, but not total body fat or VAT, was identified as an 
independent predictor of insulin resistance among both adolescents and adults 
68
. An elegant 
study by Fabbrini et al., examined the independent association of VAT and IHTG to metabolic 
function. They demonstrated increased VLDL-TG secretion and impaired insulin action in adipose 
tissue, skeletal muscle and liver of obese subjects with high IHTG, but not among those with high 
VAT matched for IHTG. Furthermore high IHTG was associated with altered expression and protein 
levels of CD36 (a protein involved in fatty acid metabolism) in adipose tissue and skeletal muscle, 
suggesting a role in ectopic fat accumulation. The authors concluded that IHTG, not VAT, is a better 
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indicator of metabolic functionality associated with obesity 
69
. In later work this group examined the 
impact of weight gain among obese individuals defined by IHTG and insulin sensitivity as MHO and 
MUO 
70
. Both groups were challenged with a high-fat diet to achieve ~6% weight gain. Despite 
similar fat mass increases there were distinct differences in the response to weight gain between the 
groups. Insulin sensitivity in adipose tissue, liver and skeletal muscle deteriorated and blood pressure, 
plasma TG, VLDL apoB100 concentrations and secretion rates increased among the MUO, but not 
the MHO individuals, suggesting that MHO subjects are protected against the adverse effects of 
weight gain. Such protection may be derived from the increased biological pathways and genes 
associated with adipose tissue lipogenesis observed among the MHO, but not the MUO, individuals 70. 
From this evidence it seems that body composition and fat distribution, in particular VAT and hepatic 
fat, are both important players in determining cardiometabolic health status.  
Diet and lifestyle factors  
Environmental factors such as diet, physical activity, alcohol consumption and smoking play a role in 
the development of obesity. Simply put excessive caloric intake coupled with low levels of physical 
activity and/or increased sedentary time give rise to a positive energy balance leading to increased 
body fat accumulation. In the context of MHO diet, including dietary composition, dietary patterns 
and dietary quality, has been fairly widely studied. However the evidence supporting the role of diet 
in MHO has been surprisingly inconsistent to date. Interestingly similar total energy intake and 
dietary macronutrient intakes have been reported in MHO and MUO individuals 
39, 71-73
, leading 
researchers to examine dietary patterns, indices of dietary quality and compliance with dietary 
recommendations. A recent cross-sectional study involving 2415 middle-aged Australian adults 
reported that for every one standard deviation increase in the healthy dietary pattern, the likelihood of 
having a more metabolically healthy profile increased by 16% (OR 1.16, 95% CI 1.04-1.29) 
74
. Using 
NHANES data (2007-2008 and 2009-2010) Camhi et al., examined dietary quality assessed by the 
Healthy Eating Index 2005 (HEI-2005) scores among obese adolescents (n=133) and adults (n=1102) 
21
. MHO was defined as obesity with two or less abnormal risk factors for fasting glucose, 
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hypertension, triglycerides and HDL-C 
14
. HEI-2005 scores were higher among the MHO adolescents 
and women (aged 19-44 years) relative to their MUO counterparts, whereas no differences were noted 
among MHO and MUO men (aged 19-44 or 45-85 years). Examination of scores from specific food 
groups revealed that MHO adolescents had higher milk scores and scores from added sugars, solid 
fats and alcoholic beverages. Among the 19-44 year-old women, higher scores for whole fruits, whole 
grain, meat and beans were reported. These findings highlight the potential of dietary quality indices 
as intervention targets and the importance of such intervention starting earlier in life, as differences 
were only observed among adolescents and younger women. Park et al., investigated Mediterranean 
Diet Scores (MDS) among 1739 adult participants of the National Health and Nutrition Examination 
Survey III (1988-1994) who were followed up for deaths until 2011 
75
.  Metabolic health was defined 
using the Wildman definition 
32
. Consumption of red meat and dairy products were lower among the 
MHO individuals, who also had a higher ratio of monounsaturated to saturated fatty acids, which 
contributed to their higher MDS. Furthermore, adherence to a Mediterranean style diet was associated 
with lower all-cause mortality among the MHO individuals (multivariable-adjusted hazard ratio of 
0.44, 95% confidence interval (0.26-0.75) comparing the highest tertile to the first tertile of MDS), 
but not among the MUO subjects, perhaps suggesting that alternative strategies are required for MUO. 
Given the range of MHO criteria available, we investigated in a cross-sectional cohort of 2047 
middle-aged men and women to what extent differences between metabolically healthy and unhealthy 
obese and non-obese subjects, defined using a variety of metabolic health definitions may be 
explained by dietary composition, dietary quality and food pyramid compliance 
39
. In keeping with 
previous findings total calorie intake, dietary macronutrient composition and also dietary quality were 
generally similar between the MHO and MUO individuals across MHO definitions. However better 
compliance with food pyramid recommendations was positively associated with MHO (defined by 
insulin resistance and Wildman). Furthermore, some differences in the number of daily servings of 
fruit and vegetables, dairy, meats, fats and high fat/sugar food and drinks were noted between the 
MHO and MUO subjects, depending on which MHO criteria used. Of note there was generally no 
effect of physical activity, smoking or alcohol intake observed between MHO and MUO individuals 
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across the range of MH definitions examined. Collectively these findings highlight the potential of 
dietary guidelines as intervention targets to improve cardiometabolic health status among obese 
individuals.   
Diet and lifestyle interventions 
Limited and inconsistent data regards the impact of dietary and exercise interventions in MHO exist 
76-79
. Rondanelli et al., reported significant improvements to a range of metabolic measures including 
HOMA, CRP, HDL-C, leptin, adiponectin, ghrelin, glucagon like peptide-1and fatty acid profiles 
among 103 MHO individuals following a 2 month prudent dietary intervention 
80
. Unfortunately this 
study did not include MUO individuals. Kantartzis et al., examined 262 MHO and MUO individuals, 
defined by HOMA and BMI, following a 9 month lifestyle intervention programme. Visceral fat was 
reduced in both groups post-intervention, however total body and liver fat was reduced among the 
MUO subjects only. These individuals also reported improvements in insulin sensitivity, although 
they remained insulin resistant 
77
. In contrast Ruiz et al., did not observe any differences in the 
magnitude of change in anthropometric measures between MHO (n=25) and MUO (n=53) women 
following a 12-week energy-restricted dietary intervention 
81
. Janiszewski et al., reported reductions 
in body weight, total and visceral fat mass and enhanced insulin sensitivity in both MHO (n=63) and 
MUO (n=43) subjects following a 3-6 month exercise or diet-induced weight loss intervention, with 
greater improvements in insulin sensitivity among the MUO subjects 
76
. A 5-10% reduction in body 
weight is considered to be clinically significant and as such can improve metabolic health among 
obese individuals. Lui et al., investigated the impact of a 5% lifestyle-based weight loss on the 
metabolic profiles of 392 MHO and MUO individuals 
82
. Among those who achieved target weight 
loss, improvements to most risk factors were observed regardless of metabolic health status, 
suggesting that a clinically significant weight loss is beneficial to all obese individuals.  
Cardiorespiratory fitness 
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Higher levels of cardiorespiratory fitness (CRF) are independently associated with healthier metabolic 
profiles and reduced risk of incident CVD and CVD mortality 
83-86
. However the roles of physical and 
cardiorespiratory fitness (CRF) have not been extensively investigated in the context of understanding 
the determinants of MHO status. Dalleck et al., examined metabolic syndrome components in 332 
adults before and after a supervised 14 week community-based exercise program designed to improve 
cardiometabolic risk factors 
87
. This short-term intervention, which improved cardiorespiratory fitness 
(assessed by conventional submaximal exercise test protocols for walking or cycle ergometry) and 
eliminated MetS features, positively transitioned MUO individuals to MHO status. The greatest 
results were observed among those engaging in higher volumes of exercise, suggesting community 
based exercise as an effective model for primary prevention of cardiometabolic disease. Ortega et al., 
examined fitness (assessed by a maximal exercise test on a treadmill), body fat composition and 
metabolic health status among 43, 265 adults participating in The Aerobics Center Longitudinal Study 
88
. Their findings suggest that the MHO phenotype, defined using BMI or BF%, is associated with 
better CRF in both men and women, and that once CRF level is accounted for the MHO phenotype 
may be benign in terms of mortality and morbidity risk. These authors recently reviewed the current 
evidence regards CRF and MHO from cross-sectional and longitudinal studies 
89
. They conclude that 
better CRF should be considered to be a characteristic of the MHO phenotype, signal that caution 
should be taken regards whether CRF plays a role in the prognosis of the MHO individuals, and 
recommend further investigation of the role of CRF in MHO.  
Genetics 
Limited data regards genetic predisposition to MHO exists. As mentioned already the Beijing 
Children and Adolescents Metabolic Syndrome study (BCAMS) explored the contribution of both 
genetic and environmental factors to the pathogenesis of MHO among 6-18 year olds 
30
. Although a 
limited number of genetic variants (22 single nucleotide polymorphisms (SNPs)) were examined, both 
the KCNQ1 rs227892 and rs227897 SNPs were identified as independent predictors of MHO. Each 
additional C allele of either SNP was associated with reduced risk of being metabolically healthy 
14 
 
based on both cardiometabolic risk markers (23% lower risk) and insulin resistance (24% lower risk), 
with stronger associations identified when a composite genetic predisposition score was examined.  
 Interestingly this study provided the first evidence of gene-nutrient (soft drink consumption) and 
gene-environment (with walking to school) interactions predisposing to MHO. Clearly much work 
remains to be done in this area to uncover the influence of genetics, nutrigenetics and epigenetics on 
MHO pathogenesis. Berezina et al., examined potential relationships between genetic variants of the 
adipocytokine genes (leptin, leptin receptor and adiponectin) and  metabolically healthy (without 
CVD) abdominal obesity among adults 
90
. Although genetic associations and gene-nutrient 
interactions have been described previously between genetic variants of these genes and MetS 
91, 92
, 
this study identified for the first time a more than two fold greater likelihood of MUO among the T 
allele carriers of the adionectin T45T polymorphism relative to the G allele carriers.  Genetic 
predisposition to weight and metabolic health related traits has been investigated longitudinally in 
almost 4000 adult and 1380 adolescent participants of the Norwegian HUNT2 (1995-1997) and 
HUNT3 (2006-2008) surveys 
93
. Examination of 27 SNPs previously associated with obesity, eating 
disorders or metabolic risk revealed novel genetic associations between a number of genes involved in 
regulation of food intake and energy expenditure, eating behaviour, food reward and satiety with 
longitudinal changes in BMI/WC and development of adverse metabolic phenotypes. Such data 
highlight the importance of not only improving our current understanding of the genetics but also the 
neurobiology of body weight regulation in the context of developing future strategies to combat 
obesity, and especially MUO.  
 
Stability of metabolically healthy obesity across the life course 
MHO was initially regarded as a static condition and, although some individuals can maintain their 
metabolic health status over time, it is becoming increasingly evident that MHO status is transient in 
nature. It has been suggested that the MHO phenotype starts in childhood and persists into adulthood. 
The Bogalusa Heart Study is unique in the context of examining MHO stability over time, in that the 
1098 individuals participated in the study both as children (aged 5-17 years) and also as young adults 
15 
 
(24-43 years), with an average follow-up of 24 years (range 14.1-28.6 years) 
16
. Importantly this study 
provides the opportunity to examine what happens to MHO status as we age from childhood, through 
adolescence into adulthood. The results are intriguing. The MHO children display similar favourable 
cardiometabolic profiles when adults relative to their childhood MUO counterparts. On the other hand 
the MUO children had the worst cardiometabolic profiles as adults. Although adult MHO status was 
maintained in only 13% of the MHO children, the MHO children were 2.7-9.3 times more likely to be 
MHO adults compared to children from the other metabolic health categories. Even though the MHO 
children displayed intermediate levels of insulin, glucose and blood pressure as adults, suggesting 
intermediate risk of T2DM and hypertension, examination of carotid intima media thickness (CIMT), 
a marker of atherosclerosis, did not reveal increased CIMT in adulthood 
16
.  As the cardiometabolic 
profiles of MHO adults have been shown to be more favourable than that of metabolically unhealthy 
normal weight individuals and more comparable to those of their normal weight counterparts, a better 
understanding of what factors contribute to achieving and maintaining good metabolic health from 
childhood into adulthood is critical.  
As already mentioned while some individuals can retain MHO status over time a substantial 
proportion of individuals with MHO cannot and may become metabolically unhealthy. Indeed, it is 
possible for any individual to transition between metabolically healthy and unhealthy states regardless 
of their BMI. Such transitions may also contribute to the observed disparity in MHO prevalence, 
inverse association with age and conflicting findings regards cardiometabolic and mortality outcomes. 
Longitudinal investigations suggest that MUO is a progressive phenotype along which MHO 
represents a dynamic intermediate stage. Data from some of the earlier studies indicate that MHO 
status is transient for about a third of individuals. Follow-up (5.5-10.3 years) of the North West 
Adelaide Health Study cohort of 4,056 adults revealed that 33% of the MHO subjects became MUO 
over time, whereas for the remaining individuals persistent MHO status was associated with 
favourable cardiometabolic outcomes 
94
. In keeping with these findings data from the Pizarra study 
indicate that 37% of MHO subjects were no longer metabolically healthy after a 6-year follow-up 
95
. 
More recent data suggest that the numbers of MHO individuals becoming unhealthy over time are 
16 
 
actually greater. Longitudinal follow-up of the Tehran Lipid and Glucose Study revealed that 43.3% 
of the metabolically healthy abdominally obese transitioned to MUO over a 10 year period 
96
. Data 
from the English Longitudinal Study of Ageing indicate that 44.5% of the MHO individuals became 
MUO over the 8-year follow-up 
97
. Consistent with these findings data from the San Antonio Heart 
Study suggest that almost half (47.6%) of MHO subjects at baseline transitioned to MUO over the 
follow-up period (median 7.8 years) 
98
.  
Characterisation of the factors which distinguish those who progress to or maintain MHO from those 
who transition from MHO to MUO may uncover potential intervention targets. In the San Antonio 
Heart Study those who transitioned were older, had lower HDL cholesterol levels and increased 
adiposity compared to the individuals with persistent MHO 
98
.  Interestingly none of the adiposity 
measures (BMI, waist circumference and weight gain) were significant predictors of this change
98
. 
Moreover, lipid profiles emerged as the strongest determinants of metabolic health status likely to 
develop with weight gain. In addition to baseline lipid concentrations (triglycerides and HDL-
cholesterol), findings from the Tehran Lipid and Glucose Study indicate that insulin resistance is a 
significant predictor of the change from MHO to MUO 
96
.  Additional predictors have been identified 
in the English Longitudinal Study of Ageing. Compared to those with persistent MHO, those who 
converted to MUO were more likely to have high blood pressure, display increased abdominal 
adiposity and have elevated levels of C-reactive protein, glycated haemoglobin and triglycerides 
97
. 
Collectively these findings highlight the importance of healthy lipid and inflammatory profiles in 
achieving and maintaining optimal cardiometabolic health. Further characterisation of persistent 
metabolic health status and longitudinal investigation of the sustainability and predictors of the MHO 
phenotype over the life course is warranted.  
 
MHO and long term health outcomes  
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The individual and joint contributions of metabolic health and BMI on long term cardiometabolic 
health outcomes and mortality are yet to be fully elucidated and further investigation is required. A 
large systematic review and meta-analysis of 2.88 million individuals confirmed significantly higher 
all-cause mortality with obesity when all grades are combined 
99
. However, examination of individual 
obesity grades revealed that grade 1 obesity (BMI 30 to < 35 kg/m
2
) was not associated with higher 
mortality. These conflicting findings may be partly explained by the existence of different obesity 
associated metabolic health phenotypes. Examination of trends in metabolic health in the Northern 
Sweden MONICA study from 1986 to 2009 demonstrated that more people are becoming overweight 
and obese, and that a larger proportion of those individuals are metabolically healthy 
100
, which has 
been suggested may reduce the impact of obesity  as a CVD risk factor 
101
. Supporting this idea, a 20 
year follow-up of the Atherosclerosis Risk in Communities Study recently reported intermediate risk 
for stroke, coronary heart disease and survival probability in individuals with suboptimal health (≤ 2 
cardiometabolic risk factors), between that of the healthy and unhealthy subgroups , with no effect of 
BMI 
102
, suggesting  that metabolic health may be more important than BMI in the context of adverse 
cardiometabolic outcomes.  
Findings from prospective studies tracking the development of CVD, T2DM and mortality in MHO 
have been inconsistent 
101, 103-108. Thus whether MHO represents true health among obese individuals 
is controversial and remains the subject of ongoing debate 
109-112
. Examination of all-cause and CVD 
mortality after 17.7 years follow-up of the Whitehall II cohort of 5,269 adults aged 39-62 (prevalence 
of MHO 9-41% depending on definition used) revealed  that both the MHO and MUO subjects had 
increased mortality risk (hazard ratio (HR) ranged from 1.81; 95% CI 1.16–2.84 to 2.30; 95% CI 
1.13–4.70 for MHO and from 1.57; 95% CI 1.08–2.28 to 2.05; 95% CI 1.44–2.92 for the MAO) 
relative to the metabolically healthy normal weight subjects 
106
. Furthermore, increased risk of both 
incident CVD and T2DM was reported among MHO individuals relative to their healthy normal 
weight counterparts 
113
. However, the MHO individuals were at a lower risk of T2DM but not CVD, 
compared to the MUO subjects. Thus MHO may not be as benign as initially thought and results are 
largely dependent on what outcome is examined and what reference group is used. In the Uppsala 
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Longitudinal Study of Adult Men (30 years follow-up of 1,758 subjects) increased mortality risk was 
identified in obese subjects with and without the MetS (2.4 and 1.7 fold higher, respectively) relative 
to the normal weight participants without the MetS 
103
. The Third National Health and Nutrition 
Examination Survey (NHANES III) (8.7 years follow-up of 6,011 subjects), reported similar 
increased mortality risk (approximately 2.8-fold) between obese participants with ≤1MetS feature and 
obese subjects with ≥2 MetS features relative to their metabolically normal non-obese counterparts 
107
. Furthermore using waist circumference rather than BMI to classify obesity, follow-up (average 
time of 13.4 years) of the EPIC-MORGEN cohort of 22,654 individuals aged 20-59 years revealed 
higher mortality risk among metabolically healthy abdominally obese (MHAO) subjects relative to 
their metabolically healthy non-obese (MHNAO) counterparts (HR 1.43; 95% CI 95% 1.00-2.04) 
108
. 
Similar HRs were obtained for the metabolically unhealthy not abdominally obese subjects 
(MUNAO) (HR 1.31; 95% CI: 1.08-1.59), whereas higher HRs were identified for the metabolically 
unhealthy abdominally obese (MUAO) subjects (HR 1.99; 95% CI: 1.62-2.43 NS) 
108
. Moreover, the 
Study of Women’s Health across the Nation (SWAN) of 475 middle-aged women reported greater 
subclinical CVD burden among the metabolically healthy overweight/obese subjects relative to the 
MHNO women 
114
. Collectively these findings suggest that obese subjects, whether metabolically 
healthy or not, and regardless of how MHO is defined carry greater risk of CVD and mortality and 
thus MHO may not be as apparently healthy as originally considered.  
Conversely several studies have not reported higher risk of CVD and all-cause mortality among their 
MHO participants. Seven year follow-up of 22,303 men and women (mean age 54.1 years) from the 
Health Survey for England and Scottish Health Survey failed to demonstrate increased risk of CVD 
(HR 1.26; 95% CI 0.74-2.13) or all-cause mortality (HR 0.91; 95% CI 0.64-1.29) among MHO 
subjects (defined by NCEP ATP III, the Wildman definition and BMI) relative to their metabolically 
healthy non-obese counterparts 
101
. Of note increased risk of all-cause mortality was observed among 
the MUO individuals (HR 1.72 95%CI 1.23-2.41) compared to the MHO subjects. Similar results 
were obtained when WC was used to define obesity. Calori et al., in a follow-up of 2,011 middle-aged 
adults over 15 years, reported increased CVD, cancer and all-cause mortality risk (HR 1.40; 95% CI 
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1.08-1.81) among the obese insulin resistant individuals, but not in the obese insulin sensitive (MHO) 
subjects relative to their non-obese insulin sensitive counterparts 
104
. In addition to higher prevalence 
of CVD, greater severity of angiographic CAD has also been reported  in a study of 856 Korean 
subjects among the metabolically unhealthy (defined by NCEP ATPIII) obese or normal weight 
subjects compared to the MHO or MHNO groups 
115
. Examination of mortality risk in NHANES III 
(12-18 years follow-up of 4,373 men and women) demonstrated that MHO individuals (defined 
according to HOMA, NCEP ATP III, Karelis definition) were not at increased risk of all-cause 
mortality compared to the MHNO individuals 
105
. More recently Guo et al., investigated the relative 
impact of  body weight and metabolic health on health outcomes using data from 2 large cohorts 
(Coronary Artery Risk Development in Young Adults Study and the Atherosclerosis Risk in 
Communities Study, with 18.7 and 20 years follow-up, respectively) 
102
. They reported lower risk for 
T2DM, CVD, stroke and mortality among the MHO individuals relative to the MUO subjects, but 
increased diabetes risk compared to the MHNO subjects. Clearly the data on long term impact of 
MHO on cardiometabolic health and mortality risk is conflicting, which may be at least partly due to 
differences in study design, obesity classification, MHO definitions and reference groups. Whether 
obesity or metabolic health is a more important predictor of future health and/or disease remains 
unclear and further investigation of obesity associated metabolic health phenotypes is warranted.  
 
MHO: role in risk stratification and personalised treatment? 
Obesity is a multifaceted public health problem; the sheer complexity of the interacting biological, 
environmental and social determinants has been nicely illustrated by the UK Foresight obesity 
systems map 
116
. However, it is becoming apparent that the situation is further complicated at a 
personal level by the existence of subtypes of obesity based on an individuals’ metabolic health status. 
Despite an ever increasing evidence base which has highlighted potential intervention points 
including food production and consumption, physiology, individual physical activity, the physical 
activity environment, and both individual and social psychology, obesity prevalence continues to rise. 
20 
 
This begs the question of whether more personalised strategies to combat obesity, based on an 
individual’s metabolic health background, may offer new opportunities in obesity diagnosis, 
intervention and treatment. 
The existence, clinical utility and limitations of the MHO phenotype have been widely questioned and 
debated 109-112, 117-119. While the lack of a universally accepted MHO definition and usefulness of BMI 
to accurately classify obesity are clearly pertinent issues, the concept that any form of obesity could 
be described as healthy is controversial. In a recent commentary Rey-Lopez argued that “more efforts 
must be allocated to reducing the distal and actual causal agents that lead to weight gain, instead of 
the current disproportionate scientific interest in the biological processes that explain the 
heterogeneity of obesity” 112. However perhaps the heterogeneity of obesity, in terms of an 
individuals’ phenotype and inter-individual differences in responsiveness to dietary or lifestyle 
interventions, should not be ignored. Recent evidence indicates that despite similar overall dietary 
intake between metabolic health subtypes that favourable lifestyle factors including higher dietary 
quality, healthy diet pattern, greater compliance with food pyramid recommendations, being less 
sedentary and more (moderately) physically active may all be positively associated with MHO 
21, 39, 74, 
120
. Interestingly examination of stable and unstable MHO suggests that a healthy lifestyle index may 
determine transition to MUO 
121
. Furthermore a recent proteomics study identified dysregulated 
inflammatory and lipid processes as molecular hallmarks of MHO 
122
, confirming earlier findings that 
MHO individuals display more favorable lipoprotein 
123
 and inflammatory profiles 
65
. Collectively 
such investigations may identify new behavioural and biological targets which may aid the 
development of more effective evidence based risk stratification, intervention and treatment strategies 
to reduce both obesity and its metabolic complications.  
Supporting this concept, the American Association of Clinical Endocrinologists (AACE) in 2014 
suggested a complication-centric approach to the management of weight loss, whereby more 
aggressive therapeutic approaches for those patients with obesity-related complications were 
advocated 
124
. More recently the AACE and the American College of Endocrinology (ACE), 
21 
 
motivated according to the Chair of the AACE Obesity Scientific Committee by “the lack of 
comprehensive and evidence-based guidelines to real-world clinical care of patients with obesity”, 
have developed new clinical practice guidelines (CGP) which acknowledge the need for a more 
individualised treatment approach to obesity 
125
. These evidence-based CPGs address a range of 
aspects of obesity care including screening, diagnosis, clinical evaluation, treatment options, selection 
and goals. A notable shift here is the additional target of improving metabolic health rather than just 
weight loss per say. This development is timely, as it is evident that up to now approaches focussed 
on preventing and/or attenuating obesity and body weight have not achieved much success in halting 
the rising tide of obesity. While data on the impact of the new guidelines on the obesity epidemic will 
take some time to filter through it seems likely that high risk groups, such as the MUO who carry the 
greatest risk of both adverse cardiometabolic and mental health outcomes 
101, 102, 104, 105, 115, 126
, could 
really benefit from such risk stratification. However, if metabolic health is a more important driver of 
future health than obesity it could be argued that improving metabolic health and attenuating 
development of cardiometabolic disease in intermediate risk subgroups (with or without obesity), such 
as MHO and metabolically unhealthy non-obese individuals, may also be worthwhile. 
 
Conclusions 
It is clear that a great body of research on obesity-associated metabolic health phenotypes has been 
performed to date. However much remains to be done. Despite the knowledge that different obesity 
subtypes exist the research community has been slow to refine obesity and metabolic health 
definitions. While advances in the development of new obesity treatment guidelines are encouraging 
whether these will have the desired impact on reducing obesity and its complications remains to be 
seen. Better understanding of both the lifestyle determinants of MHO and the molecular mechanisms 
that mediate the MHO phenotype is warranted. To advance the state-of-the-art future research will 
need to focus on these issues from a life course perspective, as well as conducting larger evidence-
22 
 
based lifestyle intervention studies and longitudinal follow-up, with a view to opening up new 
avenues of personalised obesity medicine. 
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Figure 1 
 
 
In this model it is hypothesized that the body’s coping mechanism to a positive energy balance, 
arising from a combination of excessive caloric intake, increased levels of sedentary behaviour and 
reduced physical activity, may determine an individual’s predisposition to MHO or MUO. The 
pathway to MUO may be characterised by dysfunctional adipose tissue, increased immune cell 
infiltration and reduced capacity of subcutaneous adipose tissue to expand leading to increased 
ectopic fat deposition resulting in lipotoxicity, insulin resistance in peripheral tissues and a range of 
metabolic derangements. Adapted from McMorrow et al., 
62
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